Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03407144 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 3 months later Nov 6, 2026 → Feb 12, 2027
See other at-risk trials from Merck (MSD)

Record History

The 50 most recent of 117 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Nov 6, 2026 to Feb 12, 2027
  2. Lead sponsor: Merck Sharp & Dohme LLC to Merck Sharp & Dohme LLC Interventions: Radiotherapy (RT) (Radiation), bleomycin (Drug), cyclophosphamide (Drug), dacarbazine (Drug), doxorubicin (Drug), etoposide (Drug)… to Radiotherapy (RT) (Radiation), bleomycin (Drug), cyclophosphamide (Drug), dacarbazine (Drug), doxorubicin (Drug), etoposide (Drug)… · Eligibility criteria expanded, about 26 words · Secondary endpoints: 10 to 9 · 1 more Show 4 more changesShow less
    • Interventions: Radiotherapy (RT) (Radiation), bleomycin (Drug), cyclophosphamide (Drug), dacarbazine (Drug), doxorubicin (Drug), etoposide (Drug)… to Radiotherapy (RT) (Radiation), bleomycin (Drug), cyclophosphamide (Drug), dacarbazine (Drug), doxorubicin (Drug), etoposide (Drug)…
    • Eligibility criteria expanded, about 26 words
    • Secondary endpoints: 10 to 9
    • Site details revised at 23 of 93 sites
  3. Primary and study completion dates: Feb 13, 2027 to Nov 6, 2026v115
  4. 3 versions Re-verified since Dec 1, 2023, no change to tracked fieldsv112-v114
  5. Trial status: Recruiting to Active, Not Recruiting Site details revised at 93 of 93 sitesv111 Show 1 more changeShow less
    • Site details revised at 93 of 93 sites
Show 43 earlier versionsHide 43 earlier versions
  1. Site details revised at 2 of 93 sitesv110
  2. Site details revised at 1 of 93 sitesv109
  3. Site details revised at 2 of 93 sitesv108
  4. Site details revised at 5 of 93 sitesv107
  5. Site details revised at 3 of 93 sitesv106
  6. Site details revised at 2 of 93 sitesv105
  7. Site details revised at 1 of 93 sitesv104
  8. Site details revised at 2 of 93 sitesv103
  9. Site details revised at 5 of 93 sitesv102
  10. Site details revised at 2 of 93 sitesv101
  11. Site details revised at 1 of 93 sitesv100
  12. Site details revised at 2 of 93 sitesv99
  13. Site details revised at 1 of 93 sitesv98
  14. Study sites revised (93)v97 See this version in full on ClinicalTrials.gov ↗
  15. Study sites: 92 to 93v96
  16. Site details revised at 1 of 92 sitesv95
  17. Study sites: 91 to 92v94
  18. Eligibility criteria revised Site details revised at 1 of 91 sitesv93 Show 1 more changeShow less
    • Site details revised at 1 of 91 sites

    See this version in full on ClinicalTrials.gov ↗

  19. Site details revised at 2 of 91 sitesv92
  20. Site details revised at 1 of 91 sitesv91
  21. Site details revised at 2 of 91 sitesv90
  22. Site details revised at 1 of 91 sitesv89
  23. Site details revised at 1 of 91 sitesv88
  24. Site details revised at 1 of 91 sitesv87
  25. Site details revised at 1 of 91 sitesv86
  26. Site details revised at 1 of 91 sitesv85
  27. Enrollment target: 440 to 340 Site details revised at 1 of 91 sitesv84 Show 1 more changeShow less
    • Site details revised at 1 of 91 sites
  28. Re-verified, no change to tracked fieldsv83
  29. Study sites: 90 to 91v82
  30. Study sites: 88 to 90v81
  31. Study sites: 87 to 88v80
  32. Study sites: 86 to 87v79
  33. Study sites: 85 to 86v78
  34. Study sites: 84 to 85v77
  35. Site details revised at 2 of 84 sitesv76
  36. Site details revised at 2 of 84 sitesv75
  37. Study sites: 83 to 84v74
  38. Site details revised at 1 of 83 sitesv73
  39. Site details revised at 1 of 83 sitesv72
  40. Study sites: 81 to 83v71
  41. Site details revised at 1 of 81 sitesv70
  42. Study sites: 80 to 81v69
  43. Study sites: 79 to 80v68
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Merck (MSD)
407 trials monitored
See 29 trials at risk
Hodgkin Lymphoma
287 trials monitored
See 26 trials at risk
This study will examine the safety and efficacy of pembrolizumab (MK-3475) in combination with chemotherapy in children and young adults with newly diagnosed classical Hodgkin Lymphoma (cHL) who are slow early responders (SERs) to frontline chemotherapy.
Trial Details
NCT Number NCT03407144
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Hodgkin Lymphoma
Enrollment 340 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov